Award
National Institute of Allergy and Infectious Diseases 1R01AI203549-01
LANCET-HBV: Hepatitis B Infection in the Era of Long-Acting ART
Recipient
National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH
Award Amount
$673,177.00
Ceiling
$673,177.00
Awarded
August 04, 2026
Identifier
1R01AI203549-01
Award for a research project studying hepatitis B reactivation risks in HIV patients on long-acting ART, including clinical and behavioral studies, managed by NIH/NIAID.
Description
Research project on Hepatitis B and HIV therapy aiming to identify risks of hepatitis B reactivation in HIV patients on long-acting ART. It involves clinical, virologic, behavioral, and cost-effectiveness studies, leveraging the ACTG LANCET clinical trial (A5433). The project will develop guidelines and tools for HBV screening and monitoring during HIV therapy transitions.